A Phase I/II Trial of IMA970A Plus CV8102 Following a Single Pre-vaccination Infusion of Cyclophosphamide in Patients With Very Early, Early and Intermediate Stage of Hepatocellular Carcinoma After Any Standard Treatments.
Phase of Trial: Phase I/II
Latest Information Update: 22 Oct 2017
At a glance
- Drugs CV 8102 (Primary) ; HepaVac 101 (Primary) ; Cyclophosphamide
- Indications Liver cancer
- Focus Adverse reactions; First in man; Pharmacodynamics
- 26 Sep 2017 New source identified and integrated (European Clinical Trials Database; EudraCT2015-003389-10).
- 20 Sep 2017 Status changed from not yet recruiting to recruiting.
- 13 Sep 2017 Planned initiation date changed from 15 Aug 2017 to 1 Sep 2017.